- On Sept. 2, the U.S. Food and Drug Administration (FDA) approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting. Read more.
- On Aug. 27, the FDA approved Repatha (evolocumab) injection for some patients who are unable to control their low-density lipoprotein (LDL) cholesterol with current treatment options. Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder